PSA testing, while useful to screen for prostate cancer, may leave you and your patients with more questions than answers.
That’s where genetic testing comes in.
Integrating germline genetic testing with PSA testing can help identify patients who may have a genetic predisposition to prostate cancer.
Additionally, genetic testing may help you determine whether or not a tumor biopsy is needed.
That helps limit invasive interventions and prevent potential complications.
Patients under active surveillance may require frequent office visits, screenings, or changes to their treatment regimen.
With genetic testing, you can use results to risk stratify those with more aggressive disease progression and:
Identify patients in need of more urgent care. Some with particular genetic mutations may benefit from radiation or surgical intervention to reduce the risk of metastasis, improving prognosis and quality of life.
Discern patients eligible for new treatments. PARP inhibitors recently received FDA approval for the treatment of BRCA- or HRR-mutated mCRPC after previous therapies have failed.
Tailor screening measures. Establish how often a patient requires screening, or discover the need for additional cancer screenings, such as pancreatic cancer.